Industry Overview

Japan myocardial infarction market was valued at $159.2 million in 2025 and is projected to reach $310.9 million by 2035, growing at a CAGR of 7.0% from 2026 to 2035. Myocardial infarction continues to represent a significant public health challenge in Japan, largely due to the country’s rapidly aging population and the rising prevalence of cardiovascular risk factors such as hypertension, diabetes, and sedentary lifestyles. These factors are contributing to an increasing incidence of cardiac events, thereby driving demand for effective diagnostic and treatment solutions. The market comprises a broad range of commercially monetized products, including interventional cardiology devices such as catheters and stents, implantable cardiac devices like pacemakers and implantable cardioverter defibrillators, pharmacological therapies, and adjunct monitoring systems. Japan’s well-established healthcare infrastructure, characterized by widespread access to hospitals equipped with advanced catheterization laboratories, is enabling the rapid adoption of minimally invasive procedures, further strengthening market growth.

Interventional cardiology remains central to myocardial infarction management in Japan, supported by continuous advancements in imaging and device technologies that enhance procedural precision and patient outcomes. In August 2025, GE HealthCare introduced the Vivid Pioneer, an advanced AI-powered cardiovascular ultrasound system designed to improve diagnostic accuracy and clinical workflow efficiency. The system offers high-resolution 2D and 4D cardiac imaging along with automated analysis capabilities, allowing clinicians to make more informed decisions during cardiac assessments. Such technological innovations are playing a critical role in enabling early detection and effective management of cardiovascular conditions, including myocardial infarction. Alongside these advancements, increasing healthcare expenditure and strong reimbursement frameworks are supporting sustained adoption of advanced medical technologies across hospitals and specialty cardiac centers, contributing to the steady expansion of the myocardial infarction market in Japan.

Market Dynamics

Minimally Invasive Interventions Powering MI Treatment Growth

Interventional procedures dominate the market due to the widespread adoption of percutaneous coronary intervention (PCI) for myocardial infarction treatment. Devices such as catheters, guidewires, and stents play a critical role in restoring coronary blood flow and improving patient outcomes. In March 2026, Otsuka Medical Devices announced that its Paradise Ultrasound Renal Denervation system received National Health Insurance coverage and was commercially launched in Japan. This catheter-based technology reduces blood pressure by targeting overactive renal nerves, offering a novel treatment approach for resistant hypertension. Such advancements support cardiovascular risk reduction and indirectly contribute to lowering myocardial infarction incidence across Japan.

Smart Cardiac Monitoring & Emergency Support Driving Adjunct Care Growth

Adjunct and supportive care is experiencing strong growth driven by the rising adoption of advanced cardiac monitoring and post-treatment solutions across hospitals and specialty centres. Technologies such as defibrillators, ECG systems, and remote monitoring tools are enhancing real-time patient management and clinical decision-making. In February 2026, Nihon Kohden Corporation showcased its CPR assist and ventilation solutions through a promotional release, focusing on improving emergency response in critical care settings. These systems support effective cardiopulmonary resuscitation and stabilization during acute cardiac events, including myocardial infarction. Such innovations are strengthening adjunct care infrastructure and improving survival outcomes in emergency cardiac care.

Market Segmentation

• Based on treatment type, the market is segmented into pharmacological treatment, interventional procedures, and adjunct & supportive care.
• Based on medical device type, the market is segmented into left ventricular assist device, pacemaker, catheters, implantable cardioverter defibrillator, and others.
• Based on end-user, the market is segmented into hospitals, specialty centres, and ASCs.

Drug Therapies Driving Long-Term Cardiac Care

Pharmacological treatments play a critical role in the management of myocardial infarction, particularly in reducing the risk of recurrence and improving patient survival. Widely used drug classes such as antiplatelets, anticoagulants, and thrombolytics form the foundation of post-MI treatment protocols. These therapies help prevent blood clot formation, restore blood flow, and stabilize cardiovascular function. Their continued use in both acute and long-term care settings ensure better clinical outcomes and reduced complications. As a result, pharmacological interventions remain an essential component of comprehensive myocardial infarction management.

Market Players Outlook

The major companies operating in the japan myocardial infarction market include Johnson & Johnson, Abbott, Medtronic, Siemens Healthineers, and GE HealthCare, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In August 2025, Abbott Laboratories received CE Mark approval in Europe for the expanded use of its Navitor TAVI system to treat patients with severe aortic stenosis across all surgical risk categories. The minimally invasive valve replacement technology significantly broadens patient eligibility and supports the shift toward catheter-based cardiac interventions. Such advancements strengthen interventional cardiology capabilities, indirectly supporting myocardial infarction treatment infrastructure across hospitals and specialty cardiac centres.

• In January 2024, Medtronic received CE Mark approval for its next-generation Micra AV2 and VR2 leadless pacemakers, enhancing cardiac rhythm management solutions. These devices offer nearly 40% longer battery life and improved programming capabilities, reducing complications associated with traditional pacemakers. Such advancements support improved post-myocardial infarction care and remote patient monitoring, contributing to the growth of advanced cardiac device adoption.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Key companies operating in the Japan myocardial infarction market
• Based on the availability of data, information related to new protections and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.